Drug Trial Radar · NCT03559257
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
Last checked: Nov 20, 2026Latest source record: Jul 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
463
Actual
Start
Jul 31, 2018
Primary completion
Jun 19, 2019
Study completion Sep 19, 2019
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
Conditions
- Migraine
Interventions
GalcanezumabDrug
Administered SC.
PlaceboDrug
Administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Mean Change From Baseline in the Number of Monthly Migraine Headache DaysTime frame: Baseline, Month 1 through Month 3
Locations
69 sites in 13 countries. Site status is shown where the registry gives one.
21st Century Neurology
Phoenix, Arizona
Medical Center for Clinical Research
San Diego, California
Sensible Healthcare
Ocoee, Florida
University of South Florida
Tampa, Florida
Renstar Medical Research
Wesley Chapel, Florida
Boston Clinical Trials
Boston, Massachusetts
Michigan Head, Pain and Neurological Institute
Ann Arbor, Michigan
Clinical Research Institute
Minneapolis, Minnesota
Healthy Perspectives Innovative Mental Health Services, PL
Nashua, New Hampshire
Bio Behavioral Health
Toms River, New Jersey
Albuquerque Clinical Trials
Albuquerque, New Mexico
Rochester Clinical Research, Inc.
Rochester, New York
PharmQuest
Greensboro, North Carolina
Lehigh Center for Clinical Research
Allentown, Pennsylvania
Coastal Carolina Research Center, Inc.
Mt. Pleasant, South Carolina
Foothill Family Clinic
Salt Lake City, Utah
Health Research of Hampton Roads Inc
Newport News, Virginia
Northwest Clinical Research Center
Bellevue, Washington
Algemeen Ziekenhuis St Jan Brugge
Bruges, Belgium
Universitair Ziekenhuis Brussel
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Okanagan Clinical Trials
Kelowna, British Columbia, Canada
Aggarwal and Associates Ltd
Brampton, Ontario, Canada
DIEX Recherche Sherbrooke, Inc
Sherbrooke, Quebec, Canada
Neurologicka ambulance, Neurologie Brno s.r.o.
Brno, Czechia
Brain-Soultherapy s.r.o
Kladno, Czechia
DADO MEDICAL, s.r.o.
Prague, Czechia
Neurologicka ordinace
Prague, Czechia
Institut Neuropsychiatricke Pece
Prague, Czechia
Clintrial, s.r.o.
Prague, Hl. M. Praha, Czechia
Hôpital de Cimiez
Nice, France
CHU St Etienne Hopital Nord
Saint-Etienne, France
CHRU de Lille- Hôpital Roger Salengro
Lille, Cedex, France
Charité Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Essen
Essen, Germany
DRK-Kliniken Nordhessen
Kassel, Hesse, Germany
Praxis Dr. Philipp Stude
Bochum, North Rhine-Westphalia, Germany
Universitätsklinikum Jena
Jena, Thuringia, Germany
SE Neurologiai Klinika
Budapest, Hungary
Orszagos Idegtudomanyi Intezet
Budapest, Hungary
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.